uniQure N.V.

NasdaqGS:QURE 주식 보고서

시가총액: US$285.4m

uniQure 관리

관리 기준 확인 1/4

uniQure CEO는 Matt Kapusta, Dec2016 에 임명되었습니다 의 임기는 7.92 년입니다. 총 연간 보상은 $ 6.58M, 9.6% 로 구성됩니다. 9.6% 급여 및 90.4% 보너스(회사 주식 및 옵션 포함). 는 $ 1.91M 가치에 해당하는 회사 주식의 0.67% 직접 소유합니다. 1.91M. 경영진과 이사회의 평균 재임 기간은 각각 1.5 년과 7.2 년입니다.

주요 정보

Matt Kapusta

최고 경영자

US$6.6m

총 보상

CEO 급여 비율9.6%
CEO 임기7.9yrs
CEO 소유권0.7%
경영진 평균 재임 기간1.5yrs
이사회 평균 재임 기간7.2yrs

최근 관리 업데이트

Recent updates

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

Oct 21

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 06

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 09

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 03
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

uniQure: The Valuation Got More Attractive

Feb 01

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

Jan 17
Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Dec 15
A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Aug 27
Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Aug 06
Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Aug 02
Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Jul 02
uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

Jun 28
Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Apr 11
Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Mar 01
News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Dec 09
Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

Sep 21

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Aug 30

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Aug 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Aug 08

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Jun 08
These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 04
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications

Apr 08

We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

Mar 04
We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Feb 27
The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Is uniQure (NASDAQ:QURE) A Risky Investment?

Feb 23
Is uniQure (NASDAQ:QURE) A Risky Investment?

uniQure: Betting On Hemophilia-B Cure

Jan 18

CEO 보상 분석

Matt Kapusta 의 보수는 uniQure 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$285m

Mar 31 2024n/an/a

-US$297m

Dec 31 2023US$7mUS$635k

-US$308m

Sep 30 2023n/an/a

-US$228m

Jun 30 2023n/an/a

-US$187m

Mar 31 2023n/an/a

-US$157m

Dec 31 2022US$6mUS$609k

-US$127m

Sep 30 2022n/an/a

-US$125m

Jun 30 2022n/an/a

-US$114m

Mar 31 2022n/an/a

US$324m

Dec 31 2021US$5mUS$583k

US$330m

Sep 30 2021n/an/a

US$321m

Jun 30 2021n/an/a

US$303m

Mar 31 2021n/an/a

-US$139m

Dec 31 2020US$4mUS$585k

-US$125m

Sep 30 2020n/an/a

-US$166m

Jun 30 2020n/an/a

-US$136m

Mar 31 2020n/an/a

-US$124m

Dec 31 2019US$4mUS$548k

-US$124m

Sep 30 2019n/an/a

-US$105m

Jun 30 2019n/an/a

-US$103m

Mar 31 2019n/an/a

-US$92m

Dec 31 2018US$3mUS$502k

-US$83m

Sep 30 2018n/an/a

-US$90m

Jun 30 2018n/an/a

-US$78m

Mar 31 2018n/an/a

-US$78m

Dec 31 2017US$4mUS$468k

-US$79m

보상 대 시장: Matt 의 총 보상 ($USD 6.58M )은 US 시장( $USD 1.48M ).

보상과 수익: 회사가 수익성이 없는 동안 Matt 의 보상이 증가했습니다.

CEO

Matt Kapusta (52 yo)

7.9yrs

테뉴어

US$6,584,919

보상

Mr. Matthew Craig Kapusta, also known as Matt, serves as Director of Genezen Laboratories, Inc. since July 2024. He served as Independent Director at Decibel Therapeutics, Inc. since March 2023 until Septe...

리더십 팀

이름위치테뉴어보상소유권
Matthew Kapusta
CEO & Executive Director7.9yrsUS$6.58m0.67%
$ 1.9m
Christian Klemt
CFO, Principal Financial Officer & GM of Amsterdam Site3.4yrsUS$2.12m0.16%
$ 444.5k
Richard Porter
Chief Business & Scientific Officer1.1yrsUS$2.62m0.068%
$ 194.6k
Jeannette Potts
Chief Legal & Compliance Officer and Corporate Secretary1.5yrsUS$2.54m0.022%
$ 64.0k
Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germanyno data데이터 없음데이터 없음
Amin Abujoub
Chief Technical Operationsless than a year데이터 없음데이터 없음
Tamara Tugal
Business Development Director16.4yrs데이터 없음데이터 없음
Erin Boyer
Chief People & Culture Officerless than a year데이터 없음데이터 없음
Maria Cantor
Chief Corporate Affairs Officer2.7yrsUS$1.22m데이터 없음
Walid Abi-Saab
Chief Medical Officer1.4yrs데이터 없음0.24%
$ 675.4k
Eileen Sawyer
Vice President of Global Medical Affairsno data데이터 없음데이터 없음

1.5yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: QURE 의 관리팀은 경험 (평균 재직 기간 1.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름위치테뉴어보상소유권
Matthew Kapusta
CEO & Executive Director9.8yrsUS$6.58m0.67%
$ 1.9m
Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany10.3yrs데이터 없음데이터 없음
Leonard Post
Independent Non-Executive Director4.4yrsUS$412.46k0.033%
$ 93.7k
Michael Hayden
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Katherine High
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Jack Kaye
Independent Non-Executive Director8.4yrsUS$424.96k0.013%
$ 38.1k
Jesús Prieto
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Robin Ali
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Madhavan Balachandran
Independent Non-Executive Director7.2yrsUS$412.46k0.049%
$ 139.2k
Jeremy Springhorn
Independent Non-Executive Director7.2yrsUS$424.96k0.049%
$ 139.2k
David Meek
Independent Chairman of the Board6.4yrsUS$444.96k0.042%
$ 118.7k
Robert Gut
Non-Executive Director6.1yrsUS$404.96k0.091%
$ 258.8k

7.2yrs

평균 재임 기간

71yo

평균 연령

경험이 풍부한 이사회: QURE 의 이사회는 경험(평균 재직 기간 7.2 년)으로 간주됩니다.